Marksans Pharma Gets USFDA nod for Diabetes Treatment Tablets
New Delhi : Marksans Pharma has received approval from the US health regulator for its Metformin Hydrochloride tablets, used for treatment of diabetes, in the American market.
The company has been granted the US Food and Drug Administration (USFDA) approval for Metformin Hydrochloride extended release tablets in the strengths of 500 mg and 750 mg, Marksans Pharma said in a BSE filing.
The product is generic version of Bristol Meyers Squibb's Glucophage XR extended release tablets in the same strengths, it added.
"The annual sale of the product is approximately USD 230 million," the drug firm said.
The tablets are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type II diabetes.
Shares of Marksans were trading 10.16 per cent up at Rs 50.40 apiece on BSE.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd